General Medicine: Open Access

ISSN - 2327-5146

Can use Golgi protein 73(GP73), as serum biomarker for early surveillance of hepatocellular carcinoma in first stage and chronic liver diseases in Saudi Arabia Patients

Global Physicians and Healthcare Congress

June 25-27, 2018 Dubai, UAE

Randa Mohamed MA Farag; Dujana AlAyobi; Khalid A Alsaleh; Hye-Joo Kwon, Afaf EL-Ansary and Emad A. Dawoud

Assistant Prof and Cancer bioermrkers researcher, Health Scinces Resraech Center (HSRC), Princess Nourah Bint Abdulrahman University (PNU), Riyadh, KSA
Prof of Genetic, Biology department, Princess Nourah bint Abdulrahman University (PNU),Riyadh, Kingdom Saudi Arabia (KSA)
Prof of Oncology and Hematology, college of Medicine, King Saud University (KSU), Kingdom Saudi Arabia (KSA)
Assistant Prof of molecular biology, Princess Nourah bint Abdulrahman University (PNU), Kingdom Saudi Arabia (KSA)
Prof Biochemistry, Central Labe, King Saud University (KSU); elansary@ksu.edu.sa
Assistant Prof of Hepatopathology at Faculty of Medicine EL-Azher University and Specialist Physician, Oncology Clinic-Medical Affaies, Tawam Hospital, AL Ain, UAE

Posters & Accepted Abstracts: Gen Med

Abstract :

This study was performed to quantify the expression of Golgi protein-73 (GP73) in healthy controls and in patients with liver disease, and to evaluate the correlations between GP73 and other serum markers in different liver diseases. Study the sensitivity and specificity of Golgi Glypican-73 (GP37) as new biomarker useful in early prediction for Hepatocellular Carcinoma in hepatitis viruses (HBV, HCV) and in chronic liver Cirrhosis; Also in chronic liver diseases. Serum GP73 was measured in 478 healthy controls and 296 patients with different types of liver disease. Quantitative hepatitis B virus (HBV) DNA was determined in two chronic hepatitis B (CHB) groups. Other serum liver fibrosis markers were measured in the liver fibrosis group and �?±-fetoprotein (AFP) was measured in hepatocellular carcinoma (HCC) group. The correlations between GP73 and these markers were evaluated. The GP73 value in hepatitis B e antigen (HBeAg)-positive CHB group, HBeAgnegative CHB group, liver fibrosis group and HCC group was significantly higher (p<0.001) than that in healthy controls. GP73 showed significant correlation with other markers in the liver fibrosis group and with AFP in the HCC group. Compared with healthy controls, GP73 in patients with liver disease was significantly increased. With the progression of liver disease, GP73 showed a significantly increasing trend. These results suggest that GP73 might be used as a serum marker for the diagnosis of liver diseases and for monitoring disease progression. Acknowledgement The authors would like to thank King Abdul Aziz City for Science and Technology (KACST) for supporting the present work as part of NTPC funded projects No. AT-34-208.

Biography :

Randa MA farag has completed his PhD at 2016 from Zagazeig University and postdoctoral studies from Hellwan University, Medical Scincese. She is researcher in Health Science Research Center, Princess Nourah Bint Abdulrahman University.

E-mail: randa792006@gmail.com

Top